Suppr超能文献

PARK8 阳性帕金森病的有效长期丘脑底核刺激。

Effective long-term subthalamic stimulation in PARK8 positive Parkinson's disease.

出版信息

J Neurol. 2010 Jul;257(7):1205-7. doi: 10.1007/s00415-010-5493-8. Epub 2010 Feb 23.

Abstract

Whether patients with genetically defined Parkinson's disease (PD) may be particularly eligible to benefit from deep brain stimulation of the nucleus subthalamicus (STN-DBS) is currently the subject of debate. We report on a patient with advanced PD due to R793M missense mutation in the LRRK2 gene successfully treated by STN-DBS. Disease onset was at age 42 with bradykinesia, rigidity and rest tremor. During the course of the disease he developed severe motor fluctuations, dyskinesias, postural instability with falls, but preserved levodopa responsiveness. At age 60 the patient was treated by bilateral DBS of the STN. At one year after surgery a 66% improvement of the UPDRS motor score in the off-medication state was determined. During the long-term follow-up there was sustained benefit with 56% improvement of motor score after 8 years. Our report adds evidence that patients with LRRK2 monogenetic Parkinsonism are well suited candidates for DBS treatment and may indicate a potential genetic predictor for positive long-term effect of STN-DBS treatment.

摘要

是否患有遗传性帕金森病(PD)的患者可能特别适合接受核下丘(STN)深部脑刺激(DBS)治疗,这是目前争论的焦点。我们报告了一名患有 LRRK2 基因突变(R793M 错义突变)导致的晚期 PD 患者,该患者通过 STN-DBS 成功治疗。疾病在 42 岁时发作,表现为运动迟缓、僵硬和静止性震颤。在疾病过程中,他出现了严重的运动波动、运动障碍、姿势不稳伴跌倒,但仍保留对左旋多巴的反应性。在 60 岁时,患者接受了双侧 STN-DBS 治疗。术后一年,停用药物时 UPDRS 运动评分改善了 66%。在长期随访中,8 年后运动评分改善了 56%,持续受益。我们的报告提供了证据表明,LRRK2 单基因帕金森病患者是 DBS 治疗的理想候选者,这可能表明 STN-DBS 治疗的长期效果存在潜在的遗传预测因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验